H ê s § ´ Ë á ¯ á Z q- 3 - 9 ¬28 ã9Ô ã9Õ%Y2 ã"á 99æ00 - 109æ40 . 6 * Z f39æ ë...

820 9 27 13 00 17 00 18 00

9 28 9 00 13 00

060-8638 15 7

9 27 1

13 00 - 13 10

13 10 - 14 30 1

13 10 - 13 30 1Osteopontin promoter SNPs nt

13 30 - 13 50 2

1) 2) 2) 3) 3) 3)

4) 4) 4) 5)

1) 2) 3) 4)

5)13 50 - 14 10 3

osteopontin1) 1) 1) 2) 3)

3) 3) 4) 1) 1)

1) 1) 1)

Department of Cenllular and Molecular Pathology, German Cancer Research

Center 3) 4)

14 10 - 14 30 4 HIV OPN

Haorile Y Chagan1) 1) 1) Shenwei Li1), 2)

3) 3) 1),2) 1)

1) 2) ( ) 3)

14 30 - 15 30 2

14 30 - 14 50 5

1) 1), 2) 1), 2) 3) 3)

3) 3) ) 3) 1)

14 50 - 15 10 6(OPN)

1) 1) 2) 3) 4) 4)

5) 1) 1) 1) 5)

4) Shau-Ku Huang2) 1)

1) 2) Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA 3)4) 5)

15 10 - 15 30 79

15 30 - 15 40

15 40 - 17 00

(Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School)

18 00 -

9 28 2

9 00 - 10 40 3

9 00 - 9 20 84 9

9 20 - 9 40 99

9 40 - 10 00 10

1) 1) 1) 1) 2)

2) Susan R. Rittling3), David T. Denhardt3), 1)

3) Departments of Genetics and Cell Biology and Neuroscience,

Rutgers University, Piscataway, NJ, USA.

10 00 - 10 20 11

1) 2) 2) 2) 2)

10 20 - 10 40 129

1) 1) 1) 1) 2) 1)

10 40 - 10 50

10 50 - 11 50

10 50 - 11 10 13

1) 2) 1) 1),3) 2)

1) 2) 3)

11 10 - 11 30 14

1) 2) 3) 2) 3)

11 30 - 11 50 15 Osteopontin is dispensable for protection against high load systemic

fungal infection Ikuko Sato1), Nobuchika Yamamoto2), Susan R. Rittling5), David T. Denhardt5),

Motohiro Hino3), Junko Morimoro6), Fumihiko Sakai4), Akihiko Fujie1), and

Toshimitsu Uede6)

3) 4) 5) Rutgers University, Nelson

Laboratories 6)

11 50 - 12 00

Osteopontin promoter SNPs nt -155

CTh1 osteopontin cytokine

osteopontin

osteopontin promoter 100 nt-155, -616, -1,748 3SNPs nt -443 SNP HepG2

promoter assay nt -155, nt -443 SNPs nt -155 deletion mutation allele G PCnt -155 Y SRY HNF-3/fkh homolog HFH FoxD3

HepG2 gel-shift assaynt -155 deletion mutation oligonucleoside SRY, FoxD3

allele G SRY Heladeletion mutation FoxD3

osteopontin nt -155 alleleSNPs

1) 2) 2) 3) 3) 3) 4)

4) 4) 5)

1) 2) 3) 4) 5)

viable

OPN OPN G-156Del

(DCM) 120(%FS)

%FS 5% DCM 80OPN, ANP OPN G-156Del

PCR-RFLP OPN ANP(p<0.00001) OPN G156 (

%; Del/Del 37%, Del/G + G/G 67%, p=0.006)OPN

OPN G-156Del

osteopontin

1) 1) 1) 2) 3) 3) 3)

4) 1) 1) 1) 1) 1)

1) 2) Department of Cenllular and Molecular Pathology, German Cancer Research Center 3)4)

OPN OPN(OPN N-half)

OPN (OPN-Full) OPN N-half

2008 2 615 OPN-Full OPN N-half CRP IL-6

( ) ( )

71.3 4.8 14 OPN-Full 557157 810 267 ng/ml p<0.001 OPN N-half CRP IL-6

( 0.246 0.151, 0.210 0.121 mg/dl, p=0.073, IL-6 3.00 4.10, 3.00 1.61 pg/ml, p>0.999) OPN

(LSL LB-4225, C OPN-N (IBL 11108)

OPN-FullN-half

HIV OPN

Haorile Y Chagan1) 1) 1) Shenwei Li1), 2) 3) 3)

1),2) 1)

1) 2) ( ) 3)

HIV CD4HAART

(IRS)HAART proinflammatory cytokine OPN

HAARTOPN

OPN - (GAL-9)HIV/ B (HBV) HIV(PCP) (MTB) (KS)

HAART 3 HAART80

HIVOPN GAL-9 PCP

OPN PCP GAL-9HAART GAL-9

OPN IRSHAART OPN

1) 1), 2) 1), 2) 3) 3) 3)

3) ) 3) 1)

1) 3)2) 4)

OPN (EAU)(C57BL/6; B6) EAU OPN

RNA OPN

B6 (hIRBP1-20:GPTHLFQPSLVLDMAKVLLD) 200 g

0.1 g EAU OPN (M )400 g/ IgG RNA

OPN siRNA (OPN-siRNA) siRNA (control-siRNA 50 g/ (1 ml PBS) hydrodynamichIRBP1-20 3H-thymidineELISA

M5 EAU B6M5 T

IFN- TNF- OPN siRNA M5

IFN- TNF- OPN-siRNAEAU T

- 10 -

1) 1) 2) 3) 4) 4) 5)

1) 1) 1) 5) 4) Shau-Ku Huang2)

1) 2) Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA 3) 4)

OPN Th1Th2

OPNOPN OPN

OPN (2K1) -4 (P1H4)OPN (M5)

OPN (p 0.005)(r=0.530,p 0.01) OPN (p 0.01) 2K1

P1H4 (p 0.01) M5 BAL(p 0.05)

(RA)(OPN)

9 (55A2C)9

RA CAIA ( ) CAIA9 mRNA

FACS (FLS) 9FLS 9 (OPN, -C)9 FLS IL-6, IL-1

mRNA CAIA55A2C 9 in vivo

( )55A2C IL-6, IL-1

9 FLS9 RA

- 12 -

Harvey Cantor Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School, Boston, U. S. A.

(OPN)OPN

(DC)OPN OPN OPN

AUG AUG

OPN OPN (plasmacytoid DC/pDC) TLR9 IRF-7

IFN (conventional DC/cDC) OPN IL-27IL-17 (Th17)

OPN in vivo pDC OPN IFNcDC OPN Th17

(EAE) OPN

- 13 -

(OPN) 4 9Ser162-Val-Val-Tyr-Gly-Leu-Arg168(SVVYGLR) OPN

(MMP) -3,-7 Arg168/Ser169 Gly166/Leu167SVVYGLR 4

Leu167 9 Tyr165OPN SVVYGLR 4 9

SVVYGLR Alanine4 9

Val164 Tyr165 Leu167 4 9Arg168 9

9 OPNMMP OPN N 4 9

Arg168 9Arg168 (R168A) 4 9

Arg168 4 9

- 14 -

APC APC9

TGF T9 IL-12p40 T

- 15 -

1) 1) 1) 1) 2) 2) Susan R. Rittling3),David T. Denhardt3), 1)

1) 2)3) Departments of Genetics and Cell Biology and Neuroscience, Rutgers University, Piscataway, NJ, USA.

(OPN)hUVEC in vitro OPN

in vivo OPNhUVEC SVVYGLR

OPN OPN( KO ) (n = 32) ( WT ) (n = 32)

3 7 14Platelet/endothelial cell adhesion molecule-1

(PECAM-1)

SVVYGLROPN

PECAM-1 KOWT (0.164 (+/-0.096) mm WT 0.478 (+/-0.193) mm)

SVVYGLR OPNOPN OPN

- 16 -

1) 2) 2) 2) 2) 2)

(KO ) (WT )

F4/80 SMA

3 6 8 10 12 KOKO 6 8

3 6 8 KO WTKO WT F4/80 SMA

- 17 -

1) 1) 1) 1) 2) 1)

3 1, 5 1, 6 49 1

9 (55A2C) 9

9-C in vivo 9

(NHG) 55A2C

55A2C CD3155A2C CD31

55A2C 55A2C

in vitro 955A2C

- 18 -

1) 2) 1) 1),3) 2) 1)

1) 2) 3)

IL-1, IL-6 TNF-

(OPN)(A/PR/8 (H1N1))

(A/Aichi/2/68(H3N2)) OPNOPN A/PR/8

A/Aichi/2/68 OPNA/Aichi/2/68

A/PR/8 OPNOPN A/PR/8

OPNOPN in vitro

OPNOPN

- 19 -

1) 2) 3) 2) 3) 4) 4)

1) 2) 3)4)

(interstitium)

(OPN)OPN

OPN OPNOPN

(KO ) (WT C57BL/6J wild type)OPN

(C57BL/6J ) (O ) (C )8 11 12 sacrifice

OPN ( ) WTKO (mg)(mm2) ( m) WT KO 1/2

KO OPN( ) C O

C O 1/3 1/3O C 1/2

OPN OPNOPN OPN

OPN OPN

- 20 -

Osteopontin is dispensable for protection against high load systemic fungal infection

Ikuko Sato1), Nobuchika Yamamoto2), Susan R. Rittling5), David T. Denhardt5), Motohiro Hino3), Junko Morimoro6), Fumihiko Sakai4), Akihiko Fujie1), and Toshimitsu Uede6)

1) 2) 3) 4) 5) Rutgers University, Nelson Laboratories 6)

RGDSLAYGLR

M5 J Clin Invest. 2003;112(2):181-8. M5

Antimicrob Agents Chemother. 2005 49(7):3053-5.

370-0831 5 1TEL: 027-310-8040 FAX 027-310-8045

osteopontin@ibl-japan.co.jp

H ê s § ´ Ë á ¯ á Z q- 3 - 9 ¬28 ã9Ô ã9Õ%Y2 ã"á 99æ00 - 109æ40 . 6 * Z f39æ ë...

Documents

> v ] v P Z v Á } l W W ít Z Á o v W d Z u } ( Z v Á } l ' ] À v W Z Z ] µ } ( Z v Á } l

#=LVWQRYLQ - نمره برترdl.nomrebartar.com/12/jozve/zist/Jozve_12_Zist_f4_nom... · 2020. 6. 5. · ÊfiY Á cZ Z¸ Y { ÌÌ¤e ½YÂÀ #]LVWQRYLQ Z¨ Á f¯{ ºÌ Àe Á ÄÌÆe

^ Á ] Z } v } o · Á ] Z X ^ Ç ] v P ] v Z ] U ( ] v v ^^ Á ] Z _ U v Z v ^ E Á ^ Á ] Z _ X z } µ Á ] o o Z } Á v ï }

> v ] v P Z v Á } l W W íbhiksha/courses/deeplearning/Spring.2018/www/… · t Z Á o v W d Z u } ( Z v Á } l ' ] À v W Z Z ] µ } ( Z v Á } l

2017 - Edl · R"-&-"01$%&>(,,&/$&%$81+;8(/,$&:+%&>$"%(;F& v Zo r Z] v Z} U o v Zo Z} Xt Á]oo }À] U µ $"-&-"01$%&(8&$;-+6%"F$@&#+&/%(;F&#*$(%&+>;&

t Z ] Z } ( Z ] } v u Z Z ] Z M · 2020-04-19 · t v Ç , ] } Ç t Z } Á } µ ] M t Z Z À ] } v o } } l Z Á ] } µ v v Á Z Ç } µ ] Á } ] P v ] . v X

%$6(6 /2$'(' - Manchester Softballmanchester-softball.co.uk/wp-content/uploads/2016/02/25.18.pdf · } µ v v / Z v l Z v À Ç } v ( } v ] v P X d Z Á Z Á o Ç l v } Á Á Z } Á

Help File (002) - Clients - igrs.mcxindia.com Guide - Clients.pdf · î ô X z } µ Á ] o o Z v ] À u P } ( µ ( µ o Z v P } ( Á } X v Z v Á W Á } v Z Z Z r v Z v Á W Á }

BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB · W v µ Z ] u s o µ ( ^ Z Á v P Z ( Á ] Z } o Á v X ] µ Z ( º Z µ v P ,/s rd } o o

;( F E f G · Å Ë Á ´ | | W Á u u ¤ ´ Z | ¾ § ´ | à | K Á Ù Å µ ® | R ´ u § | |: ® Å Ë Á ´ | | W Á u u ¤ ´ Z |

Á # 1K j _ ^ Z g h \ _ f [ Z j ] h ^ b g _ Á ¸ Ä ® ¥ « » ¸ ¤ Á » ½ ¿ Ì Ã » « ª ½ ¼ ® ¤ ¥ ¤ À r ¥ , ( õ l í ò Ô Õ Ó Ã Ð Ã s Á # 1 & # - & ! ½ ¿

> v ] v P Z v Á } l W W íbhiksha/courses/deeplearning/... · 2017-09-06 · t Z Á o v W d Z u } ( Z v Á } l ' ] À v W Z Z ] µ } ( Z v Á } l d Z u } ( Z v Á } l Wd Z Á ] P

á á ázhu/ams571/normals_quadratics_regressions.pdfó D P ] v o ] ] µ ] } v X > z ] ] } v } Z z A» ¼ º « ¬ ª E D < < U Á Z z A z í U Y U z l d

d d > v ( ] o o ] Z P } Z K Á Z ] } ^ u W u v } ( ( ( } v ( Z Á …...d d > v ( ] o o ] Z P } Z K Á Z ] } ^ u W u v } ( ( ( } v ( Z Á µ o ] Ç v } o } P Ç ] o î ì í ó Z }

Webinar PCT distrib · Á Á Á Xandchange Xru l Á ] v W } ] X o o Z ] P Z Z À X í ñ ¤ & # * ( , / 4 ( # ( t ¿ ( % ( : = * , & A / , 9 &

ÉYÃÂÆ«É Z» ÊÅZ»| Á¾ Ê ] ½Zf qÂ¸]Á½Zf Ì ½Zf Y , Z] Ä¿Zy{Á

4th Mother Chess below 1600 - light BGmotherchess.com/assets/brochure/4th-MotherChess-1600.pdfW Ç u v D } W í X Z u ] v Z } µ P Z Á Á Á X Z ( X } u U Á Á Á X Ç ð Z X } u

Z , µ u v Z ] P Z î ì í õ ~Y o M , } Á Á ] o o o P o } o u ] u Ç...Z ] ] } v l o Á ] v µ } v o ] u ] Z µ u v ] P Z M ^ í ñ r ï ó ,Z } v } o Ç X z E } z , } Á Á ]

r u t r s z - germanwatch.orggermanwatch.org/sites/germanwatch.org/files/Empowerment for Climate... · Z W l l Á Á Á X µ v P X l µ Z µ l Á ] z P u ] v lW o u v ] Z ] E Z Z

f < @ * R z Ö 2/z Î1 Ã p Á. O 9Ô -49Õ . O T - JICA